Disease · MONDO_0000004

adrenocortical insufficiency

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adrenocortical insufficiency. Diseases, record MONDO_0000004. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000004

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adrenocortical insufficiency; Open Targets
Open Targets ID: MONDO_0000004; Open Targets
Other names: Hypoadrenalism, adrenal cortical hypofunction, adrenal cortical insufficiency, adrenal gland insufficiency, adrenal insufficiency, hypocortisolemia, hypocortisolism; Open Targets
Disease Ontology: DOID:10493; Disease Ontology
MeSH: D000309; MeSH
NCI Thesaurus: C26691; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 11 drugs, from DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HYDROCORTISONE	CHEMBL389621	Small molecule	Approval	EMA Human Drugs	17	15	15	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
COSYNTROPIN	CHEMBL2103784	Protein	Approval	TTD	1	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
ETOMIDATE	CHEMBL681	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
FENTANYL	CHEMBL596	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROCORTISONE HEMISUCCINATE	CHEMBL3989663	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
MIDAZOLAM	CHEMBL655	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Unknown	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00915343	Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency	Phase 2/3	64	2015-07-20	Adrenal Insufficiency	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT00462644	Evaluation of Etomidate on Adrenal Function in Trauma Patients	Not applicable	30	2009-11-11	Adrenal Insufficiency	ETOMIDATE, FENTANYL, MIDAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT02720952	Treatment of Adrenal Insufficiency in Children	Phase 3	24	2017-04-11	Adrenal Insufficiency	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT02733367	Extension Study for Patients Entered Into Study Infacort 003	Phase 3	18	2019-09-13	Adrenal Insufficiency	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT04621565	Hydrocortisone Use During Peri-operation for Pituitary Adenomas	Not applicable	436		Pituitary Adenoma, Adrenal Insufficiency, Surgery	HYDROCORTISONE, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00862381	Hydrocortisone Use After Etomidate in Intensive Care	Phase 3	106		Patient Admitted in Reanimation	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT07558135	The ARISE Trial Compares Whether Giving Routine Steroid Replacement or Using Targeted Blood Tests to Guide Replacement Better Protects Certain Patients From Adrenal Insufficiency After the Removal of a Diseased Adrenal Gland.	Not applicable	96		Adrenal Gland Disease	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT02277587	Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)	Phase 4	89		Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT03282487	Optimising Steroid Replacement in Patients With Adrenal Insufficiency	Phase 4	60		Adrenal Insufficiency	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT05222152	Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency	Phase 2	58		Primary Adrenal Insufficiency	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Etomidate vs Fentanyl-Midazolam: Number of Deaths	2 of 18	0 of 12	30	NCT00462644	Trial comparisons
Etomidate vs Fentanyl-Midazolam: serious adverse events	2 of 18	0 of 12	30	NCT00462644	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33821793	RESULT	1	PubMed
31853550	RESULT	1	PubMed
24944332	RESULT	1	PubMed
22112807	RESULT	1	PubMed
19383806	RESULT	1	PubMed
18784570	RESULT	1	PubMed
41874506	DERIVED	1	PubMed
41552007	DERIVED	1	PubMed
37339332	DERIVED	1	PubMed
36383383	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000004

GET https://conductscience.org/api/diseases/v1/MONDO_0000004/drugs

API reference For AI assistants